Servier Ranked Among Top Companies Across Several Categories in 2024 PatientView Corporate Reputation of Pharma Survey
U.S. recognition follows last month's announcement that Servier made the top ten list of organizations evaluated by PatientView globally
BOSTON, May 28, 2025 /PRNewswire/ — Servier today announced that the company was ranked among the top companies across several categories in PatientView's 2024 Corporate Reputation of Pharma in the U.S. survey. This annual survey captures insights from more than 350 patient organizations reflecting their firsthand experiences, perceptions and familiarity with pharmaceutical companies.
This ranking comes on the heels of PatientView's Global Reputation of Pharma Survey – where Servier earned a spot in the Top 10 of pharmaceutical company reputations among patient organizations. This marked the first time in the Top 10 globally, reinforcing our ever-increasing commitment to patients and the organizations that represent them.
'Being recognized at the top of PatientView's annual rankings is not just an honor, it's a meaningful reflection of our continued commitment to listening to patients, collaborating closely with patient advocates, and delivering solutions that truly meet needs,' said Nicolas Garnier, Chief Patient Officer, Servier. 'This recognition is a reflection of our deep, ongoing commitment to putting patients first and acknowledging the essential role they play in shaping our work at every stage. This kind of external validation reinforces that we are listening, learning, and taking the right actions to truly support patients and the communities that represent them.'
U.S. patient organizations also ranked Servier in the top two across all categories and first in several categories: Transparency on Data, Integrity, Beyond the Pill, Engagement in R&D.
Globally, Servier was also ranked among the top 10 companies – underscoring the company's growing reputation and meaningful impact on patients worldwide.
'At Servier, engaging meaningfully with patient organizations and ensuring access to medicines are fundamental priorities,' said Wendy Poage, Vice President of the Patient Office at Servier. 'We're honored to be recognized in the Patient View report for our integrity and commitment to delivering support that goes beyond the pill. This kind of external validation reinforces that we are listening, learning, and taking the right actions to truly support patients and the communities that represent them.'
For more information on Servier Pharmaceuticals patient support services, please visit servier.us/patient-support and https://www.servierone.com/.
About the Corporate Reputation of Pharma Survey
2024 'Corporate Reputation of Pharma' survey of patient groups worldwide was conducted December 2024 to March 2025 and answered by 372 US patient groups, representing over 13 million US patients during the past year. The PatientView annual Corporate Reputation of Pharma survey gives patient-advocacy groups an opportunity to comment on, and assess, the pharma industry's performance. Companies are ranked against their peers. The survey results reinforce the dedication, commitment and hard work companies invest internally to ensure engagement with patients and advocacy groups is reflective of the patients they serve.
About Servier
Servier is a global pharmaceutical group governed by a nonprofit foundation, committed to making a meaningful social impact for patients and contributing to a sustainable world.
Its unique governance model ensures its independence, while supporting long-term innovation, with 100% of its profits reinvested in the Group's development.
As a world leader in hypertension and venous diseases and major player in cardiometabolism, Servier drives transformative innovation to support patients with chronic conditions and improve their day-to-day lives through a holistic approach, which includes making patient adherence and control a priority across the globe. Its ambition is to become a leading player in rare cancers, which is why the Group invests heavily in oncology, allocating close to 70% of its R&D budget to this field. By leveraging precision medicine, Servier develops therapies that are more targeted and more effective.
Bolstered by its success in oncology, Servier has expanded into neurology, a key driver of future growth. The Group is focused on a select number of neurodegenerative diseases, where accurate patient profiling enables targeted therapeutic responses through precision medicine.
To open up wider access to high-quality, affordable care, Servier also offers an extensive range of generic medicines, building on well-established brands in France, Eastern Europe, and Brazil. In all its activities, and at every stage of the medicine life cycle, the Group integrates the patient's voice.
Headquartered in France, Servier operates in around 140 countries. In 2023-2024, the Group, which employs over 22,000 people worldwide, achieved revenues of €5.9 billion.
More information on our website : servier.com
Follow us on social media : LinkedIn, Facebook, Twitter, Instagram
Media Contact:
Sara Noonan
Sara.Noonan@Servier.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
3 hours ago
- Malaysian Reserve
Novelis Announces Results of Tender Offer for 3.250% Senior Notes due November 2026
ATLANTA, Aug. 15, 2025 /PRNewswire/ — Novelis Inc. (the 'Company') announced today the results of its indirect wholly-owned subsidiary, Novelis Corporation's (the 'Issuer') previously announced cash tender offer for any and all of its 3.250% Senior Notes due November 2026 (the 'Notes'), upon the terms and conditions included in the Offer to Purchase, dated August 11, 2025. As of the expiration time of the tender offer, which was 5:00 pm., New York City time, on August 15, 2025 (the 'Expiration Time'), the aggregate principal amount of the Notes that have been validly tendered and not validly withdrawn was $738,116,000, representing 98.4% of the $750,000,000 aggregate outstanding principal amount of the Notes, which amount includes $2,326,000 that remain subject to the applicable guaranteed delivery procedures. Holders who indicated by the Expiration Time that they will deliver their Notes through the guaranteed delivery procedures set forth in the Offer to Purchase must deliver their Notes by 5:00 p.m., New York City time, on August 19, 2025. The complete terms and conditions of the Tender Offer were set forth in the Offer to Purchase and the related notice of guaranteed delivery (the 'Notice of Guaranteed Delivery'). Subject to the terms and conditions of the tender offer being satisfied or waived, holders who validly tendered and did not withdraw Notes prior to the Expiration Time will receive the 'Tender Offer Consideration' equal to $997.50 per $1,000 principal amount of Notes. In addition to the Tender Offer Consideration, holders will receive accrued and unpaid interest on the Notes from the most recent payment of semi-annual interest for such Notes preceding the Settlement Date to, but not including, the Settlement Date. The Settlement Date is expected to be August 18, 2025. With respect to the Notes tendered and accepted for purchase, if any, pursuant to the guaranteed delivery procedures described in the Offer to Purchase, the holders of any such Notes will receive payment of the Tender Offer Consideration for such Notes, plus accrued and unpaid interest from the most recent payment of semi-annual interest for such Notes preceding the Settlement Date up to, but not including, the Settlement Date, on the settlement date for any Notes tendered pursuant to a Notice of Guaranteed Delivery, which is expected to be August 20, 2025. All accrued and unpaid interest on the Notes from the most recent payment of semi-annual interest for such Notes up to, but not including, the Settlement Date will cease to accrue on the Settlement Date for all Notes accepted for purchase pursuant to the Tender Offer, including those tendered pursuant to the Notice of Guaranteed Delivery. The Company intends to redeem any Notes that are not purchased in the tender offer in accordance with the indenture governing the Notes as more fully described in the Offer to Purchase. The Company has engaged BNP Paribas Securities Corp. to act as Dealer Manager for the tender offer. Persons with questions regarding the tender offer should contact BNP Paribas Securities Corp. toll-free at (888) 210-4358 or collect at (212) 841-3059. Requests for documents should be directed to D.F. King & Co., Inc., the Tender and Information Agent for the tender offer, at (212) 269-5550 (for banks and brokers) or (800) 967-5071 (for noteholders) or by email at LegalTeamUS@ This press release is for informational purposes only and is not an offer to purchase or a solicitation of an offer to purchase with respect to any of the Notes. The tender offer is being made pursuant to the tender offer documents, including the Offer to Purchase and Notice of Guaranteed Delivery that the Company is distributing to holders of the Notes. The tender offer is not being made to holders of Notes in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities or other laws of such jurisdiction. None of the Company, the Dealer Manager, the Tender and Information Agent or their respective affiliates is making any recommendation as to whether or not holders should tender all or any portion of their Notes in the tender offer. About Novelis Novelis Inc. is driven by its purpose of shaping a sustainable world together. We are a global leader in the production of innovative aluminum products and solutions and the world's largest recycler of aluminum. Our ambition is to be the leading provider of low-carbon, sustainable aluminum solutions and to achieve a fully circular economy by partnering with our suppliers, as well as our customers in the aerospace, automotive, beverage packaging and specialties industries throughout North America, Europe, Asia and South America. Novelis had net sales of $17.1 billion in fiscal year 2025. Novelis is a subsidiary of Hindalco Industries Limited, an industry leader in aluminum and copper, and the metals flagship company of the Aditya Birla Group, a multinational conglomerate based in Mumbai. For more information, visit Forward-Looking Statements Statements made in this news release which describe Novelis' intentions, expectations, beliefs or predictions may be forward-looking within the meaning of securities laws. Forward-looking statements include statements preceded by, followed by, or including the words 'believes,' 'expects,' 'anticipates,' 'plans,' 'estimates,' 'projects,' 'forecasts,' or similar expressions. Examples of forward-looking statements in this news release are statements about the timing and completion of the tender offer. Novelis cautions that, by their nature, forward-looking statements involve risk and uncertainty and Novelis' actual results could differ materially from those expressed or implied in such statements. Novelis does not intend, and Novelis disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Malaysian Reserve
7 hours ago
- Malaysian Reserve
Children's Hospital of Philadelphia and Children's Hospital Colorado Researchers Conduct First Prospective Study of Pediatric EoE Patients and Disease Progression
Study found that stiffness of the esophagus could serve as an important biomarker for disease progression and indicate which patients may benefit the most from current therapies PHILADELPHIA, Aug. 15, 2025 /PRNewswire/ — Researchers from Children's Hospital of Philadelphia (CHOP) and Children's Hospital Colorado have found that better control of chronic eosinophilic esophagitis (EoE)-associated inflammation during childhood leads to less stiffening of the esophagus, resulting in fewer disease complications. Using Endoluminal functional imaging (FLIP), the study team suggests this could be a key marker for assessing disease severity and progression. The findings were published online today by the journal Gastroenterology. EoE is a chronic allergic inflammatory disease of the esophagus, the muscular tube that carries food from the throat to the stomach. Children can experience nausea, regurgitation, vomiting, abdominal pain and a burning feeling like acid reflux. They may also have difficulty swallowing and gag frequently. Often, they can experience dysphagia, which is when it feels like something is stuck in their throat. If EoE goes untreated, the esophagus may narrow because of scarring, a phenomenon known as stricture. Chronic EoE-associated inflammation can lead to progressive tissue remodeling and fibrostenosis, or the narrowing of the esophagus. While clinicians recognize the severity of the disease, long-term studies looking at disease progression over time, and the impact of controlling the disease from a young age, is relatively unknown. 'This is the first study to follow kids overtime (with these endoscopic assessments) and evaluate the patients who are at the highest risk of complications,' said co-senior study author Amanda Muir, MD, a pediatric gastroenterologist in the Division of Gastroenterology, Hepatology and Nutrition at CHOP. 'With the recent FDA approval of two medications for EoE, having this data could help identify the patients who could benefit from these therapies the most and observe improvement at a histologic level over time.' Researchers at CHOP and Children's Hospital Colorado launched a longitudinal study to evaluate long-term changes in esophageal distensibility, or the ability of the esophagus to expand, in pediatric patients between the ages of 3 and 18 years old. Symptomatic, endoscopic and histologic data were collected at each visit during the study. A total of 112 patients with EoE were included with a median follow-up time of 11 months, some followed for over 4 years. 'Following children living with EoE over time has given us a clearer picture of how inflammation affects the esophagus and how treating it can improve the esophagus and outcomes for patients,' said Calies Menard-Katcher, MD, co-senior study author and Associate Director of Clinical Research for the Gastrointestinal Eosinophilic Diseases Program at Children's Hospital Colorado. 'It's exciting to see these results confirm what we've suspected in caring for patients — and they may even help us spot those at risk for more severe disease.' The study found that patients with tissue samples showing a response to treatment demonstrated the most improvement in distensibility over time. After adjusting for different factors, the study found that patients with lower esophageal distensibility had increased odds of patient-reported dysphagia, or difficulty swallowing. Patients with fibrostenosis were generally diagnosed at an older age, had the disease for a longer period and showed reduced esophageal distensibility at baseline predicted the need for future dilation in patients with strictures. The authors suggest that further studies that examine the disease from a molecular level could help them understand which patients may be at highest risk of severe disease and could benefit from a variety of treatment strategies. This study was supported by the National Institutes of Health grants R01DK124266-01, K23DK109263 and R21TR003039. Kennedy et al, 'Histologic response is associated with improved esophageal distensibility and symptom burden in pediatric eosinophilic esophagitis.' Gastroenterology. Online August 15, 2025. DOI: 10.1053/ About Children's Hospital of Philadelphia:A non-profit, charitable organization, Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, the hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. The institution has a well-established history of providing advanced pediatric care close to home through its CHOP Care Network, which includes more than 50 primary care practices, specialty care and surgical centers, urgent care centers, and community hospital alliances throughout Pennsylvania and New Jersey. CHOP also operates the Middleman Family Pavilion and its dedicated pediatric emergency department in King of Prussia, the Behavioral Health and Crisis Center (including a 24/7 Crisis Response Center) and the Center for Advanced Behavioral Healthcare, a mental health outpatient facility. Its unique family-centered care and public service programs have brought Children's Hospital of Philadelphia recognition as a leading advocate for children and adolescents. For more information, visit ABOUT CHILDREN'S HOSPITAL COLORADO Children's Hospital Colorado is one of the nation's leading and most expansive nonprofit pediatric healthcare systems with a mission to improve the health of children through patient care, education, research and advocacy. Founded in 1908 and ranked among the best children's hospitals in the nation as recognized by U.S. News & World Report, Children's Colorado has established itself as a pioneer in the discovery of innovative and groundbreaking treatments that are shaping the future of pediatric healthcare worldwide. Children's Colorado offers a full spectrum of family-centered care at its urgent, emergency and specialty care locations throughout Colorado, including an academic medical center on the Anschutz Medical Campus in Aurora, hospitals in Colorado Springs, Highlands Ranch and Broomfield, and outreach clinics across the region. For more information, visit or connect with us on Facebook, Instagram and YouTube. Contact: Ben LeachChildren's Hospital of Philadelphia(609)634-7906leachb@
Malaysian Reserve
7 hours ago
- Malaysian Reserve
Keystone Custom Homes Breaks Ground in South Carolina
CHARLOTTE, N.C, Aug. 15, 2025 /PRNewswire/ — Keystone Custom Homes is excited to announce its expansion into South Carolina, with the groundbreaking of Arbor Gate, a new community just outside of Greenville. This milestone marks the company's presence in four states across the Mid-Atlantic and Southeast. 'The entire Keystone team is honored to have our first opportunity in South Carolina being in the desirable Five Forks area of Greenville. We look forward to matching our great home plans with home buyers' ideas to build dream homes!' said Alan Banks, CEO of the Carolinas Division at Keystone Custom Homes. About Arbor Gate Located in the sought-after Five Forks area, Arbor Gate will feature 57 custom-built homes. At the heart of the community, a 6-acre park will offer walking trails, a fire pit, beautiful landscaping, and inviting gathering spaces for friends and family. With easy access to I-85 and I-385, residents can enjoy a quick commute to the city along with an abundance of nearby dining, shopping, and entertainment options. Tree-lined streets will create a peaceful, private setting while offering picturesque views. For more details, visit the Arbor Gate community page on the Keystone Custom Homes website. Upcoming Launch: The Gables at Handsmill On August 25rd, Keystone Custom Homes will debut The Gables at Handsmill in York, SC —an exclusive opportunity featuring waterfront homesites and stunning floorplans within an established community. Residents will enjoy access to a community clubhouse with a fitness center, social lounge, catering kitchen, and pool, as well as a splash pad and playground for children. Interested buyers can join the VIP list by visiting the Coming Soon page on their website. About Keystone Custom Homes Keystone Custom Homes builds award-winning custom homes across Pennsylvania, Maryland, North Carolina, and South Carolina, offering buyers the opportunity to build a home that is tailored to their lifestyle and budget. From selecting a floorplan to customizing every detail, Keystone's expert team guides buyers through every step of the process. They are dedicated to bringing dream homes to life. In 2019, founder and CEO Jeff Rutt demonstrated the company's commitment to giving back by donating 90% of Keystone's ownership to the National Christian Foundation. Through their partnership with HOPE International, Keystone supports micro-loans for underprivileged individuals globally, empowering them to start businesses and provide for their families. Together with their trade partners, expert team, and customers, Keystone Custom Homes strives to be Craftsmen for the Common Good in its communities throughout the Mid-Atlantic and Southeast.
